Preclinical study of a polyvalent vaccine against bovine mastitis

The aim of the study is a preclinical study of a polyvalent vaccine against bovine mastitis. The vaccine is made on the basis of inactivated bacteria of the strains Streptococcus uberis 3T-SD, Staphylococcus aureus 18-C, E. coli 19-SD. 6 % aluminum hydroxide gel was used as an adjuvant. During the preclinical study, the physicochemical characteristics of the vaccine, the completeness of inactivation and sterility, harmlessness, pyrogenicity, antigenic activity were studied, as well as the optimal vaccination dose of the vaccine for cows was determined and the harmlessness of a double administration of the vaccine in prophylactic and increased doses was examined. The polyvalent vaccine against mastitis is sterile, harmless for laboratory (white mice) and target (cows) animals. Its double administration promotes the synthesis of specific antibodies in the blood serum of rabbits to the Staphylococcus aureus antigen in the titer of 853.33 ± 261.28, to the Streptococcus uberis and E. coli antigens in the titers of 640.0 ± 0.0. The optimal vaccination dose of the preparation for target animals was determined on 3 groups of cows with 5 heads in each. The doses tested were 3; 5 and 7 cm3. The optimal vaccination dose of the vaccine for cows is 5 cm3 with its double administration with an interval of 14 days. After double administration of the vaccine in prophylactic and increased doses, the animals maintain a normal physiological state. They have no signs of pathological local and systemic reactions. Animals move actively, willingly take food and water, their general body temperature remains within the physiological norm.